Education
About Us
Working with TipRanks
Follow Us
Bavarian Nordic A/S (BVNRY)
OTHER OTC:BVNRY
BVNRY Stock Chart & Stats
$9.63
-$0.28(-3.01%)
At close: 4:00 PM EST
$9.63
-$0.28(-3.01%)
Day’s Range― - ―
52-Week Range$6.84 - $12.54
Previous CloseN/A
Volume6.49K
Average Volume (3M)793.00
Market Cap
$2.28B
Enterprise Value$2.37B
Total Cash (Recent Filing)$2.98B
Total Debt (Recent Filing)$134.04M
Price to Earnings (P/E)6.2
Beta1.03
Next Earnings
Mar 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.73
Shares Outstanding237,712,550
10 Day Avg. Volume0
30 Day Avg. Volume793
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.29
Price to Sales (P/S)2.58
P/FCF Ratio56.22
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue0.34
Enterprise Value/Gross Profit0.63
Enterprise Value/Ebitda0.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bavarian Nordic News
BVNRY FAQ
What was Bavarian Nordic A/S’s price range in the past 12 months?
Bavarian Nordic A/S lowest stock price was $6.84 and its highest was $12.54 in the past 12 months.
What is Bavarian Nordic A/S’s market cap?
Bavarian Nordic A/S’s market cap is $2.28B.
When is Bavarian Nordic A/S’s upcoming earnings report date?
Bavarian Nordic A/S’s upcoming earnings report date is Mar 12, 2026 which is in 83 days.
How were Bavarian Nordic A/S’s earnings last quarter?
Bavarian Nordic A/S released its earnings results on Nov 14, 2025. The company reported $0.729 earnings per share for the quarter, beating the consensus estimate of N/A by $0.729.
Is Bavarian Nordic A/S overvalued?
According to Wall Street analysts Bavarian Nordic A/S’s price is currently Overvalued.
Does Bavarian Nordic A/S pay dividends?
Bavarian Nordic A/S pays a Notavailable dividend of $0.426 which represents an annual dividend yield of N/A. See more information on Bavarian Nordic A/S dividends here
What is Bavarian Nordic A/S’s EPS estimate?
Bavarian Nordic A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bavarian Nordic A/S have?
Bavarian Nordic A/S has 237,712,550 shares outstanding.
What happened to Bavarian Nordic A/S’s price movement after its last earnings report?
Bavarian Nordic A/S reported an EPS of $0.729 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.967%.
Which hedge fund is a major shareholder of Bavarian Nordic A/S?
Currently, no hedge funds are holding shares in BVNRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bavarian Nordic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.68%
12-Months-Change
Fundamentals
Return on Equity
20.01%
Trailing 12-Months
Asset Growth
14.27%
Trailing 12-Months
Company Description
Bavarian Nordic A/S
Bavarian Nordic (BVNRY) is a biotechnology company based in Denmark that specializes in the development and commercialization of innovative immunotherapies and vaccines for infectious diseases and cancer. The company operates primarily in the biopharmaceutical sector and is known for its proprietary technology platforms, including the MVA-BN® platform, which is used to develop its lead products such as the smallpox and monkeypox vaccines, as well as cancer immunotherapies.
BVNRY Company Deck
BVNRY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in both revenue and market expansion for Bavarian Nordic, especially in the Travel Health and Public Preparedness segments. However, there were some challenges related to the refinement of financial guidance and delays affecting the U.S. launch of the chikungunya vaccine.View all BVNRY earnings summariesTechnical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Immunovant
―
Kymera Therapeutics
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
― Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---